Long-Term Outcome for Patients With High Volume Retroperitoneal Teratoma Undergoing Post-Chemotherapy Surgery

Stephen D W Beck, Richard Foster, Richard Bihrle, Lawrence Einhorn, John P. Donohue

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: We determined outcomes in patients with testicular cancer with large volume (greater than 10 cm) retroperitoneal teratoma treated with post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: A retrospective review of our testicular cancer database was performed from 1995 to 2005 to identify patients undergoing post-chemotherapy retroperitoneal lymph node dissection for residual masses larger than 10 cm with final pathological examination revealing teratoma. A total of 99 patients met the study inclusion criteria. Results: A total of 27 patients presented with disease limited to the retroperitoneum, 46 had 2 or 3 disease sites and 26 had 4 or more disease sites. Mean and median hospital stay was 7.3 and 5.0 days, respectively. There were 23 recurrences in 27 locations with the most common being pulmonary in 5, mediastinal in 5 and retroperitoneal in 5. The 2 and 5-year disease-free survival was 86% and 75% with a mean followup of 42 months. The 2-year disease-free survival for patients presenting with retroperitoneal disease only was 86% compared to 79% and 41% for patients presenting with 2 to 3 disease sites and more than 4 disease sites, respectively (p = 0.004). The 2-year disease-free survival was 78% for patients undergoing retroperitoneal lymph node dissection alone, 80% for retroperitoneal lymph node dissection plus 1 or 2 other sites and 40% for retroperitoneal lymph node dissection plus resection of 3 or more disease sites (p = 0.026). Conclusions: The recurrence rate for resected post-chemotherapy high volume teratoma is 25% at 5 years. The most common sites of recurrence are the lung, mediastinum and retroperitoneum.

Original languageEnglish
Pages (from-to)2526-2532
Number of pages7
JournalJournal of Urology
Volume181
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Teratoma
Lymph Node Excision
Drug Therapy
Disease-Free Survival
Testicular Neoplasms
Recurrence
Lung
Mediastinum
Length of Stay
Databases

Keywords

  • lymph node excision
  • teratoma
  • testicular neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Long-Term Outcome for Patients With High Volume Retroperitoneal Teratoma Undergoing Post-Chemotherapy Surgery. / Beck, Stephen D W; Foster, Richard; Bihrle, Richard; Einhorn, Lawrence; Donohue, John P.

In: Journal of Urology, Vol. 181, No. 6, 06.2009, p. 2526-2532.

Research output: Contribution to journalArticle

@article{befed0c1484045d1b382a63054f7d5c6,
title = "Long-Term Outcome for Patients With High Volume Retroperitoneal Teratoma Undergoing Post-Chemotherapy Surgery",
abstract = "Purpose: We determined outcomes in patients with testicular cancer with large volume (greater than 10 cm) retroperitoneal teratoma treated with post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: A retrospective review of our testicular cancer database was performed from 1995 to 2005 to identify patients undergoing post-chemotherapy retroperitoneal lymph node dissection for residual masses larger than 10 cm with final pathological examination revealing teratoma. A total of 99 patients met the study inclusion criteria. Results: A total of 27 patients presented with disease limited to the retroperitoneum, 46 had 2 or 3 disease sites and 26 had 4 or more disease sites. Mean and median hospital stay was 7.3 and 5.0 days, respectively. There were 23 recurrences in 27 locations with the most common being pulmonary in 5, mediastinal in 5 and retroperitoneal in 5. The 2 and 5-year disease-free survival was 86{\%} and 75{\%} with a mean followup of 42 months. The 2-year disease-free survival for patients presenting with retroperitoneal disease only was 86{\%} compared to 79{\%} and 41{\%} for patients presenting with 2 to 3 disease sites and more than 4 disease sites, respectively (p = 0.004). The 2-year disease-free survival was 78{\%} for patients undergoing retroperitoneal lymph node dissection alone, 80{\%} for retroperitoneal lymph node dissection plus 1 or 2 other sites and 40{\%} for retroperitoneal lymph node dissection plus resection of 3 or more disease sites (p = 0.026). Conclusions: The recurrence rate for resected post-chemotherapy high volume teratoma is 25{\%} at 5 years. The most common sites of recurrence are the lung, mediastinum and retroperitoneum.",
keywords = "lymph node excision, teratoma, testicular neoplasms",
author = "Beck, {Stephen D W} and Richard Foster and Richard Bihrle and Lawrence Einhorn and Donohue, {John P.}",
year = "2009",
month = "6",
doi = "10.1016/j.juro.2009.01.116",
language = "English",
volume = "181",
pages = "2526--2532",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Long-Term Outcome for Patients With High Volume Retroperitoneal Teratoma Undergoing Post-Chemotherapy Surgery

AU - Beck, Stephen D W

AU - Foster, Richard

AU - Bihrle, Richard

AU - Einhorn, Lawrence

AU - Donohue, John P.

PY - 2009/6

Y1 - 2009/6

N2 - Purpose: We determined outcomes in patients with testicular cancer with large volume (greater than 10 cm) retroperitoneal teratoma treated with post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: A retrospective review of our testicular cancer database was performed from 1995 to 2005 to identify patients undergoing post-chemotherapy retroperitoneal lymph node dissection for residual masses larger than 10 cm with final pathological examination revealing teratoma. A total of 99 patients met the study inclusion criteria. Results: A total of 27 patients presented with disease limited to the retroperitoneum, 46 had 2 or 3 disease sites and 26 had 4 or more disease sites. Mean and median hospital stay was 7.3 and 5.0 days, respectively. There were 23 recurrences in 27 locations with the most common being pulmonary in 5, mediastinal in 5 and retroperitoneal in 5. The 2 and 5-year disease-free survival was 86% and 75% with a mean followup of 42 months. The 2-year disease-free survival for patients presenting with retroperitoneal disease only was 86% compared to 79% and 41% for patients presenting with 2 to 3 disease sites and more than 4 disease sites, respectively (p = 0.004). The 2-year disease-free survival was 78% for patients undergoing retroperitoneal lymph node dissection alone, 80% for retroperitoneal lymph node dissection plus 1 or 2 other sites and 40% for retroperitoneal lymph node dissection plus resection of 3 or more disease sites (p = 0.026). Conclusions: The recurrence rate for resected post-chemotherapy high volume teratoma is 25% at 5 years. The most common sites of recurrence are the lung, mediastinum and retroperitoneum.

AB - Purpose: We determined outcomes in patients with testicular cancer with large volume (greater than 10 cm) retroperitoneal teratoma treated with post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: A retrospective review of our testicular cancer database was performed from 1995 to 2005 to identify patients undergoing post-chemotherapy retroperitoneal lymph node dissection for residual masses larger than 10 cm with final pathological examination revealing teratoma. A total of 99 patients met the study inclusion criteria. Results: A total of 27 patients presented with disease limited to the retroperitoneum, 46 had 2 or 3 disease sites and 26 had 4 or more disease sites. Mean and median hospital stay was 7.3 and 5.0 days, respectively. There were 23 recurrences in 27 locations with the most common being pulmonary in 5, mediastinal in 5 and retroperitoneal in 5. The 2 and 5-year disease-free survival was 86% and 75% with a mean followup of 42 months. The 2-year disease-free survival for patients presenting with retroperitoneal disease only was 86% compared to 79% and 41% for patients presenting with 2 to 3 disease sites and more than 4 disease sites, respectively (p = 0.004). The 2-year disease-free survival was 78% for patients undergoing retroperitoneal lymph node dissection alone, 80% for retroperitoneal lymph node dissection plus 1 or 2 other sites and 40% for retroperitoneal lymph node dissection plus resection of 3 or more disease sites (p = 0.026). Conclusions: The recurrence rate for resected post-chemotherapy high volume teratoma is 25% at 5 years. The most common sites of recurrence are the lung, mediastinum and retroperitoneum.

KW - lymph node excision

KW - teratoma

KW - testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=67349191557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349191557&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.01.116

DO - 10.1016/j.juro.2009.01.116

M3 - Article

VL - 181

SP - 2526

EP - 2532

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -